ALLOCARS Trademark

Trademark Overview

On Tuesday, September 18, 2018, a trademark application was filed for ALLOCARS with the United States Patent and Trademark Office. The USPTO has given the ALLOCARS trademark a serial number of 88122388. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 9, 2022. This trademark is owned by Allogene Therapeutics, Inc.. The ALLOCARS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy
allocars

General Information

Serial Number88122388
Word MarkALLOCARS
Filing DateTuesday, September 18, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 9, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 5, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 24, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAllogene Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameAllogene Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Monday, May 9, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 9, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, October 8, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 7, 2021SOU EXTENSION 5 GRANTED
Tuesday, September 28, 2021SOU EXTENSION 5 FILED
Monday, October 4, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 28, 2021TEAS EXTENSION RECEIVED
Thursday, March 25, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 23, 2021SOU EXTENSION 4 GRANTED
Tuesday, March 23, 2021SOU EXTENSION 4 FILED
Tuesday, March 23, 2021TEAS EXTENSION RECEIVED
Tuesday, September 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 18, 2020SOU EXTENSION 3 GRANTED
Friday, September 18, 2020SOU EXTENSION 3 FILED
Friday, September 18, 2020TEAS EXTENSION RECEIVED
Thursday, April 2, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 31, 2020SOU EXTENSION 2 GRANTED
Tuesday, March 31, 2020SOU EXTENSION 2 FILED
Tuesday, March 31, 2020TEAS EXTENSION RECEIVED
Friday, October 4, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 2, 2019SOU EXTENSION 1 GRANTED
Wednesday, October 2, 2019SOU EXTENSION 1 FILED
Wednesday, October 2, 2019TEAS EXTENSION RECEIVED
Tuesday, April 2, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 5, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 5, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 16, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 1, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 26, 2018ASSIGNED TO EXAMINER
Monday, September 24, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 21, 2018NEW APPLICATION ENTERED

Related Keywords

allocars preparations pharmaceutical including therapy immunotherapy cell tumors namely treatment cancer